Lesaka Webcast and Conference Call to Review First Quarter 2026 Results JOHANNESBURG, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Lesaka Technologies, Inc. (NASDAQ:, JSE: LSK) ("Lesaka") today announced it will release first quarter 2026 results after the U.S. market close on November 5, 2025. Lesaka management will host a presentation webcast and conference call on November 6, 2025, at 8:00am EDT (3:00pm SAST), followed by a live question and answer session for analysts and investors. Webcast Registration Link to access the results webcast: Participants using the webcast will be able to submit...
A director at Apellis Pharmaceuticals Inc sold 31,092 shares at 22.580USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
Lesaka’s Final FY2025 Results: Delivers on FY2025 Profitability Guidance, Reaffirms FY2026 Profitability & Net Revenue Outlook, and Sets FY2026 Profitability per Share Guidance, reflecting more than 100% Year-on-Year Growth JOHANNESBURG, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Lesaka Technologies, Inc. (Nasdaq: LSAK; JSE: LSK) today released results for the fourth quarter (“Q4 2025”) and full year of fiscal 2025 (“FY2025”). FY2025 performance:All growth rates are year-on-year between FY2025 and FY2024. Revenue of $659.7 million (ZAR 12.0 billion) up 14% in ZAR.Net...
Lesaka Announces Preliminary FY2025 Results, Delivers on FY2025 Profitability Guidance, Reaffirms FY2026 Profitability Outlook, and Sets FY2026 Profitability per Share Guidance, reflecting more than 100% Year-on-Year Growth JOHANNESBURG, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Lesaka Technologies, Inc. (Nasdaq: LSAK; JSE: LSK) today released preliminary unaudited results for the fourth quarter (“Q4 2025”) and full year of fiscal 2025 (“FY2025”). FY2025 performance:All growth rates are year-on-year between FY2025 and FY2024. Net Revenue (a non-GAAP measure) of $328.7 million (ZAR 5.3 billion)...
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences ALACHUA, Fla. and TAMPA, Fla., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in four upcoming investor conferences: Cantor Global Healthcare Conference (NYC)Participation: Fireside chat and 1x1 investor meetings Date/Time: Fireside Chat Wednesday, September 3, 2025, 3:20 PM ETWebcast Link: Wells Fargo Healthcare Confere...
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast fireside chats at the following investor conferences: Wells Fargo Healthcare Conference Date/Time: Wednesday, September 3, 2025 at 8:45 a.m. ET Cantor Global Healthcare Conference Date/Time: Thursday, September 4, 2025 at 8:35 a.m. ET Baird Global Healthcare ConferenceDate/Time: Tuesday, September 9, 2025 at 10:15 a.m. ET The live conference webcasts will be pos...
Lesaka to Host Webcast and Conference Call to Review Fourth Quarter and Year-End 2025 Results on September 11, 2025 JOHANNESBURG, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Lesaka Technologies, Inc. (NASDAQ:, JSE: LSK) ("Lesaka") now intends to release fourth quarter and year-end 2025 results after the U.S. market close on September 10, 2025. Lesaka management will host a presentation webcast and conference call on September 11, 2025, at 8:00am EDT (2:00pm SAST), followed by a live question and answer session for analysts and investors. Webcast Registration Link to access the results webcast: ...
Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft FDA PDUFA goal date extended by three months ALACHUA, Fla. and TAMPA, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Biologics License Application (BLA) for Avance® Nerve Graft by three months to December 5, 2025. On August 22, 2025, the Company received a communication from the FDA indicating that the information submitted by the Company in response to an FD...
Speculative Areas Still Leading; Staying Bullish We have discussed since late-July how the S&P 500 (SPX) had not closed below its 20-day MA for three months, but that even when it does, "all we would expect to happen is for a new, less-steep uptrend to form." That is precisely what has happened after the SPX finally lost its 20-day MA (for one whole day) on 8/1/25, only to get back to all-time highs last week. Therefore, we remain near-term bullish since our 4/22/25 Compass, and our intermediat...
Axogen, Inc. Reports Second Quarter 2025 Financial Results Raises Full Year Revenue Guidance to at Least 17% Growth or $219 Million ALACHUA, Fla. and TAMPA, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the second quarter ended June 30, 2025. Second Quarter Financial Results Second quarter revenue was $56.7 million, an 18.3% increase compared to the second quarter of 2024,...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.